Table 1 Patient/tumor characteristics and the use of androgen deprivation therapy (ADT) between patients without (n = 401) and with (n = 18) lymph node (LN) recurrence
Variable | Without LN | With LN |
|---|---|---|
Number (%) | Number (%) | |
Age | Â | |
 <70 | 134 (33.4) | 5 (27.7) |
 ≥70 | 267 (66.6) | 13 (72.3) |
T stage | Â | |
 1a | 5 (1.2) | 0 (0) |
 1b | 6 (1.5) | 0 (0) |
 1c | 124 (30.9) | 3 (16.7) |
 2a | 52 (13.0) | 1 (5.6) |
 2b | 40 (10.0) | 3 (16.7) |
 2c | 42 (10.5) | 0 (0) |
 3a | 72 (18.0) | 2 (11.1) |
 3b | 53 (13.2) | 7 (38.9) |
 4 | 7 (1.7) | 2 (11.1) |
Gleason score | Â | |
 <7 | 125 (31.2) | 3 (16.7) |
 7 | 185 (46.1) | 4 (22.2) |
 8–10 | 91 (22.7) | 11 (61.1) |
PSA (ng/ml) | Â | |
 <10 | 117 (29.2) | 4 (22.2) |
 10–20 | 119 (29.7) | 5 (27.7) |
 ≥20 | 165 (41.1) | 9 (50.0) |
Risk group | Â | |
 Low | 41 (10.2) | 1 (5.6) |
 Intermediate | 121 (30.2) | 1 (5.6) |
 High | 180 (44.9) | 7 (38.9) |
 Very high | 59 (14.7) | 9 (50.0) |
Any ADT | ||
 No | 57 (14.2) | 2 (11.1) |
 Yes | 344 (85.8) | 16 (88.9) |
Neoadjuvant ADT | ||
 No | 127 (31.7) | 4 (22.2) |
 Yes | 274 (68.3) | 14 (77.8) |
Concurrent ADT | ||
 No | 103 (25.7) | 8 (44.4) |
 Yes | 298 (74.3) | 10 (55.6) |
Maintenance ADT | ||
 No | 177 (44.1) | 9 (50.0) |
 Yes | 224 (55.9) | 9 (50.0) |